Management to Visit San Diego, New York, and Boston, January 16th to the 25th, 2007 HANGZHOU, China, Jan. 16 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, today announced the Company's executive team, including Chairman Jin Biao, will visit San Diego, California, January 16-17, 2007; New York, New York, January 18-22, 2007; and Boston, Massachusetts, January 23-25, 2007 to further educate the public, media and investment community about the Company's established products, ongoing research and development plans, and the attainment of previously disclosed growth objectives. Chairman of Aida Pharmaceuticals, Jin Biao, stated, "Visiting America will enable our team of executives to share the rapidly emerging growth story of Aida Pharmaceuticals and explain why we believe AIDA is an attractive investment opportunity. It is a priority for Aida's management team that we continue to be transparent to the benefit of our shareholders. Aida's goal for visiting its American investors is to provide our shareholder base with access to the Company. Aida is a profitable Company and we are gaining momentum as our potentially revolutionary cancer treatment Rh-Apo2L recently entered Phase II trials. We look forward to elaborating further on these fundamental developments, along with the recent strengthening of our competitive position in China to the media, existing and prospective retail and institutional investors this month." In each city, the Company will host meetings for interested investors and members of the public and media. Please contact Bethany Tomich at 617-723-1465 or for additional information on how to attend. About Aida Pharmaceuticals: Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China. Contact Information: Company: Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 http://www.aidapharma.com/ Investor Relations: Equity Performance Group Bethany Tomich (617) 723-1465 http://www.equityperformancegroup.com/ Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov/. DATASOURCE: Aida Pharmaceuticals, Inc. CONTACT: Bethany Tomich of Equity Performance Group, +1-617-723-1465, or Web site: http://www.aidapharma.com/

Copyright